Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Transporter DDI and Toxicity Evaluation.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SLC22A2 (OCT2) drug discovery and pharmacokinetic profiling. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLC22A2 Mutant Protein / Peptides High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View SLC22A2 Products |
| Gene Delivery | SLC22A2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Essential for multipass membrane proteins. |
View SLC22A2 Products |
| Benchmark Ab | Anti-SLC22A2 Control Antibody Recombinant positive control for expression verification. |
View SLC22A2 Products |
| Validator | SLC22A2 siRNA Set For knockdown verification in native cell lines. |
View SLC22A2 Products |
| Related Target A | SLC22A1 (OCT1) Hepatic transporter for comprehensive DDI profiling. |
View SLC22A1 Products |
| Related Target B | SLC47A1 (MATE1) Efflux transporter coupled with OCT2 in renal excretion. |
View SLC47A1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Conformation | Premade Lentivirus for robust HEK293/MDCK stable cell line generation. |
| Species Differences in DDI | Human/Mouse/Cyno ORF clones available with exact sequence verification. |
| Lack of Expression Controls | High-affinity control antibodies for Western Blot/Flow Cytometry included. |
| False Positives in Uptake Assays | Validated siRNA included for specificity checks and basal background subtraction. |
Live SLC22A2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
SLC22A2 (OCT2) is a critical renal organic cation transporter mandated by the FDA and EMA for early-stage Drug-Drug Interaction (DDI) screening. As first-generation therapies reach the clinic, the next wave of R&D is targeting mitigation of renal toxicity (e.g., cisplatin nephrotoxicity) and leveraging OCT2 for targeted drug delivery to the kidneys.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecules | Global Pharma NCEs | Oncology, Cardiovascular | Uptake Assay (Need Lentivirus for Stable Cell Lines) |
| Targeted Delivery | Specialty Biotech | Renal Diseases | Internalization Assay (Need robust cell models) |
| Protective Agents | Academic & Biotech | Cisplatin Toxicity | Inhibition Screening (Need precisely controlled expression) |